DXCM

Healthcare

Dexcom

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2009–2025(17yr)

Revenue

Net Income

Free CF

Metric	FY 2009	FY 2010	FY 2011	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$29.7M	$48.6M	$76.3M	$99.9M	$160.0M	$259.2M	$402.0M	$573.3M	$718.5M	$1.0B	$1.5B	$1.9B	$2.4B	$2.9B	$3.6B	$4.0B	$4.7B	+15.6%
Gross Profit	$3.7M	$18.4M	$35.8M	$46.6M	$100.1M	$176.3M	$278.4M	$378.4M	$492.1M	$663.9M	$931.5M	$1.3B	$1.7B	$1.9B	$2.3B	$2.4B	$2.8B	+14.9%
Gross Margin	12.3%	37.9%	47.0%	46.6%	62.6%	68.0%	69.3%	66.0%	68.5%	64.4%	63.1%	66.4%	68.6%	64.7%	63.2%	60.5%	60.1%	-0.4pp
Operating Income	-$45.8M	-$45.3M	-$44.8M	-$55.7M	-$28.9M	-$21.5M	-$57.1M	-$63.9M	-$42.5M	-$186.3M	$142.3M	$299.5M	$265.8M	$391.2M	$597.7M	$600.0M	$911.8M	+52.0%
Operating Margin	-154.4%	-93.1%	-58.8%	-55.8%	-18.1%	-8.3%	-14.2%	-11.1%	-5.9%	-18.1%	9.6%	15.5%	10.9%	13.4%	16.5%	14.9%	19.6%	+4.7pp
Net Income	-$53.5M	-$55.2M	-$44.7M	-$54.5M	-$29.8M	-$22.4M	-$57.6M	-$65.6M	-$50.2M	-$127.1M	$101.1M	$493.6M	$154.7M	$341.2M	$541.5M	$576.2M	$836.3M	+45.1%
Net Margin	-180.3%	-113.4%	-58.7%	-54.6%	-18.6%	-8.6%	-14.3%	-11.4%	-7.0%	-12.3%	6.8%	25.6%	6.3%	11.7%	14.9%	14.3%	17.9%	+3.7pp
Free Cash Flow	-$42.4M	-$49.5M	-$38.1M	-$42.6M	-$5.5M	$7.4M	$15.7M	$500.0K	$26.0M	$56.1M	$134.5M	$276.6M	$53.3M	$304.7M	$511.9M	$630.7M	$1.1B	+70.8%
FCF Margin	-142.7%	-101.9%	-50.0%	-42.6%	-3.4%	2.9%	3.9%	0.1%	3.6%	5.4%	9.1%	14.4%	2.2%	10.5%	14.1%	15.6%	23.1%	+7.5pp
EPS (Diluted)	—	$-0.89	$-0.66	$-0.78	$-0.41	$-0.29	$-0.71	$-0.78	$-0.58	$-1.44	$1.10	$5.06	$1.55	$0.82	$1.30	$1.42	$2.09	+47.2%

Total Debt$4.6M

Cash & Equiv.$917.7M

Net Cash$913.1M

4 min read

1. THE BIG PICTURE

Dexcom is attempting a high-stakes transition: moving its core technology from a niche tool for intensive insulin users into a broad-market consumer health essential for pre-diabetics. While it currently leads its peers in cash efficiency and ecosystem connectivity, it must now defend its premium valuation against a tightening regulatory environment and a fundamental shift in how the U.S. government pays for its hardware.

2. WHERE THE RISKS HIT HARDEST

Dexcom’s "clinical performance" advantage—anchored by the 8.0% MARD accuracy of its G7 system—is directly threatened by Medicare’s upcoming competitive bidding program. Starting in 2028, CMS plans to set reimbursement rates based on the 75th percentile of winning bids (Risks). This suggests that Dexcom’s technical superiority may no longer command a price premium if payers shift toward a "good enough" commodity pricing model.

Furthermore, Dexcom’s "technological leadership" is undermined by the March 2025 FDA warning letter regarding manufacturing deficiencies at its Mesa and San Diego facilities (Risks). This creates a structural vulnerability: if Dexcom cannot resolve these quality management issues, it risks production shutdowns that would derail the critical transition of its user base to the G7 system by 2026 (Competitive Position).

3. WHAT THE NUMBERS SAY TOGETHER

While Dexcom’s trailing revenue growth of 15.6% is the second-highest in its peer group, the most recent data shows a cooling trend. Fourth-quarter 2025 revenue grew by 13%, and management’s 2026 guidance forecasts a further deceleration to between 11% and 13% (Recent Results). This slowdown is occurring despite Dexcom being a highly efficient cash generator, boasting a peer-leading free cash flow (FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders) margin of 22.1% (Peer Benchmarking).

Dexcom is using this cash to return capital to shareholders, leading the group with a 2.8% buyback yield. However, this focus on buybacks stands in contrast to the significant geographic risks in its supply chain. With manufacturing heavily concentrated in Arizona, California, and Malaysia, Dexcom remains vulnerable to localized disruptions—ranging from droughts to political instability—that its current capital allocation strategy does not appear to be aggressively diversifying away from (Risks). Short interest at 4.9% of the float suggests a segment of the market remains skeptical that Dexcom can maintain its margins as growth moderates.

4. IS IT WORTH IT AT THIS PRICE?

At 22.8x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Dexcom trades at a 27% premium to the peer median of 17.9x. This premium is justified by its superior profitability; it holds the highest net margin (16.0%) and FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin (22.1%) among its primary competitors (Peer Benchmarking).

At this multiple, the market is pricing in approximately 8.5% long-term growth (CAPM analysis). This appears well-supported by Dexcom’s current trajectory, as even the low end of 2026 guidance (11%) exceeds this implied rate. However, the sensitivity is sharp: if growth were to slow to 7%, the justified multiple would drop to 17.0x, implying a 25% downside from current levels. The primary factor that could trigger such a re-rating is the 2028 Medicare reimbursement change, which could make the current 63-64% gross margin targets unsustainable.

5. WHAT WOULD CHANGE THIS VIEW?

Cautious if the FDA issues follow-up enforcement actions or product seizures, which would indicate that the manufacturing deficiencies cited in the March 2025 warning letter are not being remediated.
Constructive if 2026 operating margins exceed the guided 22-23%, signaling that the launch of Stelo for non-insulin users is achieving rapid scale without a corresponding spike in marketing costs.
Cautious if revenue growth for fiscal 2026 dips into the single digits, suggesting that the transition from G6 to G7 is resulting in higher-than-expected customer churn or pricing concessions.

6. BOTTOM LINE

Structural Advantage: A dominant "connected ecosystem" that integrates proprietary glucose sensing data with the world’s largest network of insulin pumps and consumer wearables. Bottom Line: Dexcom is a premier cash-flow machine, but its valuation leaves little room for error as it navigates a looming 2028 reimbursement cliff.

Source: Synthesis · LLM Analysis

4 min read

1. Top 5 Material Risks

Medicare Competitive Bidding: CMS has extended the DMEPOS competitive bidding program to include Dexcom CGM systems and receivers, with payment changes taking effect in 2028. This program is expected to result in lower Medicare reimbursement rates, as CMS will set payment amounts based on the 75th percentile of winning bids rather than the maximum winning bid.
Manufacturing Concentration: The majority of Dexcom manufacturing operations are located in Mesa, Arizona, and Malaysia, with limited operations in San Diego, California. A natural or man-made disaster at these sites—such as earthquakes in California, drought in Arizona, or political instability in Malaysia—could halt production and prevent Dexcom from meeting customer demand.
Regulatory Non-Compliance: In March 2025, Dexcom received an FDA warning letter citing deficiencies in manufacturing processes and quality management systems at its San Diego and Mesa facilities. Failure to resolve these issues to the FDA’s satisfaction could lead to fines, product seizures, or a complete shutdown of production.
Third-Party Payor Pricing Pressure: Managed care organizations and other third-party payors are increasingly using cost-containment measures, such as competitive bidding, bundled purchasing, and restrictive coverage policies, which could force Dexcom to accept lower net sales prices.
Product Obsolescence and Competition: The CGM market is intensely competitive, with rivals like Abbott Laboratories and Medtronic (MiniMed) introducing new technologies. If Dexcom fails to innovate or if competitors receive regulatory approval for superior or lower-cost products, Dexcom may lose market share and see a reduction in revenue.

2. Company-Specific Risks

Reliance on Single-Source Suppliers: Dexcom relies on single or sole-source suppliers for critical components, such as the application-specific integrated circuit in its transmitters and specific polymers for sensor membranes. Any interruption in these supplies could prevent the manufacturing of finished goods.
Clinical Trial Dependencies: The commercialization of next-generation products depends on successful clinical trials. Delays in patient enrollment, failure to meet safety endpoints, or disagreements with the FDA regarding trial data could prevent the launch of new products and render current inventory obsolete.
Off-Label Use Liability: While Dexcom does not promote its products for inpatient use, customers may use them in ways not described in product labeling. Such off-label use increases the risk of product liability claims and may require costly design changes to restrict unauthorized usage.
Cybersecurity and AI Integration: Integrating AI into products expands the cybersecurity attack surface. Unauthorized access to Dexcom systems or inaccurate AI outputs could lead to patient harm, regulatory penalties, and significant remediation costs.

3. Regulatory/Legal Risks

Anti-Kickback and False Claims Act: As a manufacturer of devices reimbursed by federal healthcare programs, Dexcom is subject to the federal Anti-Kickback Statute and the False Claims Act. Allegations of improper payments to referral sources or the submission of false claims could result in exclusion from Medicare and Medicaid programs.
Data Privacy Regulations: Dexcom is subject to stringent data protection laws, including HIPAA, the EU’s GDPR, and the California Consumer Privacy Act (CCPA). Non-compliance with these laws—or a data breach involving patient health information—could result in fines of up to 4% of global annual turnover under GDPR.
Physician Payments Sunshine Act: Dexcom must annually report payments and transfers of value to U.S.-licensed healthcare professionals and teaching hospitals. Failure to accurately report these interactions can lead to civil penalties.

4. Financial Impact Map

Medicare Competitive Bidding → Net Revenue → Expected to decrease Medicare reimbursement for CGM systems beginning in 2028.
Manufacturing Disruptions → Cost of Goods Sold / Inventory → Potential for increased expenses, immediate shortages, and loss of sales revenue.
Regulatory Non-Compliance (Warning Letter) → Operating Expenses → Increased costs for corrective actions and potential for fines or civil penalties.
Third-Party Payor Pricing Pressure → Net Sales Price → May force Dexcom to agree to lower net sales prices to maintain formulary placement.
Product Obsolescence → Inventory / Asset Valuation → Uncertain timing of regulatory approvals for future products could subject current inventory to excess or obsolescence charges.

Source: 10-K Item 1A · LLM Analysis

Recent Filings

Form	Filed	Period
8-K	Feb 2026	—
10-K	Feb 2026	Dec 2025
10-Q	Oct 2025	Sep 2025
14A	Mar 2025	—